ArticleCancer medicine2023

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.

Xiaomi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.